Patents by Inventor Keiko Omori

Keiko Omori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION AND METHODS FOR 3D CULTURE OF ISLET CELLS
    Publication number: 20230407265
    Abstract: Provided herein, inter alia, are compositions and methods for culturing islet cells.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 21, 2023
    Inventors: Keiko OMORI, Fouad KANDEEL, Meirigeng QI
  • PUMA, A PRO-APOPTOTIC GENE, AS A NOVEL MOLECULAR BIOMARKER FOR TNFALPHA-INDUCED HUMAN ISLET DAMAGE
    Publication number: 20180030537
    Abstract: p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-? stimulation in a time- and dose-dependent manner and ? cell apoptosis is induced through a mitochondrial pathway. TNF-? significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such ? cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
    Type: Application
    Filed: August 7, 2017
    Publication date: February 1, 2018
    Inventors: Yoko MULLEN, Masato MITSUHASHI, Keiko OMORI
  • PUMA, a pro-apoptotic gene, as a novel molecular biomarker for TNF?-induced human islet damage
    Patent number: 9758826
    Abstract: p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-? stimulation in a time- and dose-dependent manner and ? cell apoptosis is induced through a mitochondrial pathway. TNF-? significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such ? cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: September 12, 2017
    Assignees: City of Hope, Hitachi Chemical Research Center, Inc., Hitachi Chemical Co., Ltd.
    Inventors: Yoko Mullen, Masato Mitsuhashi, Keiko Omori
  • PUMA, A PRO-APOPTOTIC GENE, AS A NOVEL MOLECULAR BIOMARKER FOR TNFalpha-INDUCED HUMAN ISLET DAMAGE
    Publication number: 20110318751
    Abstract: p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-? stimulation in a time- and dose-dependent manner and ? cell apoptosis is induced through a mitochondrial pathway. TNF-? significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such ? cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 29, 2011
    Inventors: Yoko MULLEN, Masato Mitsuhashi, Keiko Omori